13278 Federal Register / Vol. 87, No. 46 / Wednesday, March 9, 2022 / Notices 

Dated: March 4, 2022. 

Tracey L. Thompson, 

Acting Deputy Director, Office of Sustainable 

Fisheries, National Marine Fisheries Service. 

[FR Doc. 2022–05002 Filed 3–8–22; 8:45 am] 

BILLING CODE 3510–22–P 

DEPARTMENT OF COMMERCE 

Patent and Trademark Office 

[Docket No. PTO–P–2022–0009] 

Grant of Interim Extension of the Term 

of U.S. Patent No. 8,858,612; Reducer®

AGENCY: United States Patent and 

Trademark Office, Department of 

Commerce. 

ACTION: Notice of interim patent term 

extension. 

SUMMARY: The United States Patent and 

Trademark Office has issued an order 

granting a one-year interim extension of 

the term of U.S. Patent No. 8,858,612. 

FOR FURTHER INFORMATION CONTACT: Ali 

Salimi, Senior Legal Advisor, Office of 

Patent Legal Administration, by 

telephone at 571–272–0909 or by email 

to ali.salimi@uspto.gov. 

SUPPLEMENTARY INFORMATION: Section 

156 of Title 35, United States Code, 

generally provides that the term of a 

patent may be extended for a period of 

up to five years if the patent claims a 

product, or a method of making or using 

a product, that has been subject to 

certain defined regulatory review, and 

that the patent may be extended for 

interim periods of up to one year if the 

regulatory review is anticipated to 

extend beyond the expiration date of the 

patent. 

On February 22, 2022, Neovasc 

Medical Ltd., the patent owner of 

record, timely filed an application 

under 35 U.S.C. 156(d)(5) for a third 

interim extension of the term of U.S. 

Patent No. 8,858,612. The patent claims 

methods of using a catheter delivered 

implantable device known by the 

tradename Reducer®. The application 

for patent term extension indicates that 

a Premarket Approval Application 

(PMA) P190035 was submitted to the 

Food and Drug Administration (FDA) on 

December 31, 2019. 

Review of the patent term extension 

application indicates that, except for 

permission to market or use the product 

commercially, the subject patent would 

be eligible for an extension of the patent 

term under 35 U.S.C. 156, and that the 

patent should be extended for one year 

as required by 35 U.S.C. 156(d)(5)(B). 

Because the regulatory review period 

will continue beyond the extended 

expiration date of the patent, March 27, 

2022, interim extension of the patent 

term under 35 U.S.C. 156(d)(5) is 

appropriate. 

An interim extension under 35 U.S.C. 

156(d)(5) of the term of U.S. Patent No. 

8,858,612 is granted for a period of one 

year from the extended expiration date 

of the ’612 patent. 

Robert Bahr, 

Deputy Commissioner for Patents, United 

States Patent and Trademark Office. 

[FR Doc. 2022–04969 Filed 3–8–22; 8:45 am] 

BILLING CODE 3510–16–P 

DEPARTMENT OF COMMERCE 

Patent and Trademark Office 

[Docket No.: PTO–P–2022–0003] 

Grant of Interim Extension of the Term 

of U.S. Patent No. 6,953,476; Reducer®

AGENCY: United States Patent and 

Trademark Office, Department of 

Commerce. 

ACTION: Notice of interim patent term 

extension. 

SUMMARY: The United States Patent and 

Trademark Office has issued an order 

granting a one-year interim extension of 

the term of U.S. Patent No. 6,953,476. 

FOR FURTHER INFORMATION CONTACT: Ali 

Salimi, Senior Legal Advisor, Office of 

Patent Legal Administration, by 

telephone at 571–272–0909 or by email 

to ali.salimi@uspto.gov. 

SUPPLEMENTARY INFORMATION: Section 

156 of Title 35, United States Code, 

generally provides that the term of a 

patent may be extended for a period of 

up to five years if the patent claims a 

product, or a method of making or using 

a product, that has been subject to 

certain defined regulatory review, and 

that the patent may be extended for 

interim periods of up to one year if the 

regulatory review is anticipated to 

extend beyond the expiration date of the 

patent. 

On February 22, 2022, Neovasc 

Medical Ltd., the patent owner of 

record, timely filed an application 

under 35 U.S.C. 156(d)(5) for a third 

interim extension of the term of U.S. 

Patent No. 6,953,476. The patent claims 

a catheter delivered implantable device, 

Reducer®. The application for patent 

term extension indicates that a 

Premarket Approval Application (PMA) 

P190035 was submitted to the Food and 

Drug Administration (FDA) on 

December 31, 2019. Review of the 

patent term extension application 

indicates that, except for permission to 

market or use the product commercially, 

the subject patent would be eligible for 

an extension of the patent term under 35 

U.S.C. 156, and that the patent should 

be extended for one year as required by 

35 U.S.C. 156(d)(5)(B). Because the 

regulatory review period will continue 

beyond the extended expiration date of 

the patent, March 27, 2022, interim 

extension of the patent term under 35 

U.S.C. 156(d)(5) is appropriate. 

An interim extension under 35 U.S.C. 

156(d)(5) of the term of U.S. Patent No. 

6,953,476 is granted for a period of one 

year from the extended expiration date 

of the ’476 patent. 

Robert Bahr, 

Deputy Commissioner for Patents, United 

States Patent and Trademark Office. 

[FR Doc. 2022–04970 Filed 3–8–22; 8:45 am] 

BILLING CODE 3510–16–P 

BUREAU OF CONSUMER FINANCIAL 

PROTECTION 

[Docket No. CFPB–2022–0017] 

Agency Information Collection 

Activities: Comment Request 

AGENCY: Bureau of Consumer Financial 

Protection. 

ACTION: Notice and request for comment. 

SUMMARY: In accordance with the 

Paperwork Reduction Act of 1995 

(PRA), the Consumer Financial 

Protection Bureau (CFPB or Bureau) 

requests the extension of the Office of 

Management and Budget’s (OMB’s) 

approval of the existing information 

collection titled ‘‘Electronic Fund 

Transfer Act (Regulation E)’’ approved 

under OMB Control Number 3170–0014. 

DATES: Written comments are 

encouraged and must be received on or 

before April 8, 2022 to be assured of 

consideration. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. In general, all 

comments received will become public 

records, including any personal 

information provided. Sensitive 

personal information, such as account 

numbers or Social Security numbers, 

should not be included. 

FOR FURTHER INFORMATION CONTACT: 

Documentation prepared in support of 

this information collection request is 

available at www.regulations.gov. 

Requests for additional information 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 46 / Wednesday, March 9, 2022 / Notices 13279 

should be directed to Anthony May, 

Paperwork Reduction Act Officer, at 

(202) 841–0544, or email: CFPB_PRA@

cfpb.gov. If you require this document 

in an alternative electronic format, 

please contact CFPB_Accessibility@

cfpb.gov. Please do not submit 

comments to these email boxes. 

SUPPLEMENTARY INFORMATION: 

Title of Collection: Electronic Fund 

Transfer Act (Regulation E). 

OMB Control Number: 3170–0014. 

Type of Review: Extension of a 

currently approved information 

collection. 

Affected Public: Businesses and other 

for-profit institutions. 

Estimated Number of Respondents: 

600,000. 

Estimated Total Annual Burden 

Hours: 3,361,056. 

Abstract: The Electronic Fund 

Transfer Act (EFTA), 15 U.S.C. 1693 et 

seq., requires accurate disclosure of the 

costs, terms, and rights relating to 

electronic fund transfer (EFT) services 

and remittance transfer services to 

consumers. Entities offering EFT 

services must provide consumers with 

full and accurate information regarding 

consumers’ rights and responsibilities in 

connection with EFT services. These 

disclosures are intended to protect the 

rights of consumers using EFT services, 

such as automated teller machine 

(ATM) transfers, telephone bill-payment 

services, point-of-sale transfers at retail 

establishments, electronic check 

conversion, payroll cards, and 

preauthorized transfers from or to a 

consumer’s account. EFTA also 

establishes error resolution procedures 

and limits consumer liability for 

unauthorized transfers in connection 

with EFT services. EFTA and Regulation 

E impose disclosure and other 

requirements on issuers and sellers of 

gift cards, gift certificates, and generaluse prepaid cards. Further, EFTA and 

Regulation E provide protections for 

consumers in the United States who 

send remittance transfers to persons in 

a foreign country. It also provides 

comprehensive protections for 

consumers who use ‘‘prepaid accounts.’’ 

Tailored provisions governing 

disclosures, limited liability, error 

resolution, and periodic statements 

added new requirements regarding the 

posting of account agreements. 

Additionally, Regulations E regulates 

overdraft credit features offered in 

connection with prepaid accounts. 

Request for Comments: The Bureau 

published a 60-day Federal Register 

notice on 12/16/2021 (86 FR 71453) 

under Docket Number: CFPB–2021– 

0021. The Bureau is soliciting 

comments on: (a) Whether the collection 

of information is necessary for the 

proper performance of the functions of 

the Bureau, including whether the 

information will have practical utility; 

(b) The accuracy of the Bureau’s 

estimate of the burden of the collection 

of information, including the validity of 

the methods and the assumptions used; 

(c) Ways to enhance the quality, utility, 

and clarity of the information to be 

collected; and (d) Ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Comments submitted in 

response to this notice will be submitted 

to OMB as part of its review of this 

request. All comments will become a 

matter of public record. 

Anthony May, 

Paperwork Reduction Act Officer, Consumer 

Financial Protection Bureau. 

[FR Doc. 2022–04953 Filed 3–8–22; 8:45 am] 

BILLING CODE 4810–AM–P 

DEPARTMENT OF DEFENSE 

Office of the Secretary 

Defense Health Board; Notice of 

Federal Advisory Committee Meeting 

AGENCY: Under Secretary of Defense for 

Personnel and Readiness, Department of 

Defense (DoD). 

ACTION: Notice of Federal Advisory 

Committee meeting. 

SUMMARY: The DoD is publishing this 

notice to announce that the following 

Federal Advisory Committee meeting of 

the Defense Health Board (DHB) will 

take place. 

DATES: Open to the public Wednesday, 

March 30, 2022 from 12:00 p.m. to 4:00 

p.m. Eastern time. 

ADDRESSES: The meeting will be held by 

videoconference/teleconference. To 

participate in the meeting, see the 

Meeting Accessibility section for 

instructions. 

FOR FURTHER INFORMATION CONTACT: 

CAPT Gregory H. Gorman, U.S. Navy, 

703–275–6060 (voice), 

gregory.h.gorman.mil@mail.mil (email). 

Mailing address is 7700 Arlington 

Boulevard, Suite 5101, Falls Church, 

Virginia 22042. Website: http://

www.health.mil/dhb. The most up-todate changes to the meeting agenda can 

be found on the website. 

SUPPLEMENTARY INFORMATION: This 

meeting is being held under the 

provisions of the Federal Advisory 

Committee Act (FACA) (5 U.S.C.), the 

Government in the Sunshine Act of 

1976 (5 U.S.C. 552b), and 41 CFR 102– 

3.140 and 102–3.150. 

Availability of Materials for the 

Meeting: Additional information, 

including the agenda, is available at the 

DHB website, http://www.health.mil/ 

dhb. A copy of the agenda or any 

updates to the agenda or the March 30, 

2022, meeting will be available on the 

DHB website. Any other materials 

presented in the meeting may be 

obtained at the meeting. 

Purpose of the Meeting: The DHB 

provides independent advice and 

recommendations to maximize the 

safety and quality of, as well as access 

to, health care for DoD health care 

beneficiaries. The purpose of the 

meeting is to provide briefings to DHB 

members on current issues related to 

military medicine and upcoming DHB 

taskings. 

Agenda: The DHB meeting will be 

called to order and begin with both 

opening and administrative remarks at 

noon. At 12:30 p.m. the discussion will 

move to mental health care access and 

recess at 1:30 p.m. for a 15-minute 

break. At 1:45 p.m., the DHB will 

discuss racial and ethnic health care 

disparities and then at 2:45 p.m. 

conclude with a discussion on virtual 

health in the Military Health System. 

After closing remarks at 3:45 p.m., the 

meeting will adjourn at 4:00 p.m. Any 

changes to the agenda can be found at 

the link provided in this SUPPLEMENTARY

INFORMATION section. 

Meeting Accessibility: Pursuant to 5 

U.S.C. 552b and 41 CFR 102–3.140 

through 102–3.165, this meeting is open 

to the public from 12:00 p.m. to 4:00 

p.m. on March 30, 2022. The meeting 

will be held by videoconference/ 

teleconference. The number of 

participants is limited and is on a firstcome basis. All members of the public 

who wish to participate must register by 

emailing their name, rank/title, and 

organization/company to 

dha.ncr.dhb.mbx.defense-healthboard@mail.mil or by contacting Ms. 

Pamela Shell at (703) 275–6012 no later 

than Wednesday, March 23, 2022. Once 

registered, the web address and audio 

number will be provided. 

Special Accommodations: Individuals 

requiring special accommodations to 

access the public meeting should 

contact Ms. Pamela Shell at least five (5) 

business days prior to the meeting so 

that appropriate arrangements can be 

made. Written Comments and 

Statements: Any member of the public 

wishing to provide comments to the 

DHB related to its current taskings or 

mission may do so at any time in 

accordance with section 10(a)(3) of the 


jspears on DSK121TN23PROD with NOTICES1